Predict your next investment

Private Equity
MOBILE & TELECOMMUNICATIONS | Telecom Services
perseus.co

See what CB Insights has to offer

Investments

104

Portfolio Exits

32

Partners & Customers

10

About Perseus

Perseus is a provider of managed services for high-precision, high-speed, high-performance applications.

Perseus Headquarters Location

110 William Street 31st Floor

New York, New York, 10038,

United States

212-300-6813

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Perseus News

Perseus Holdings USA Strengthens Board of Directors with Appointment of Veteran Biotechnology Executive Mark H.N. Corrigan, M.D.

Oct 20, 2020

News provided by Share this article AUSTIN, Texas, Oct. 20, 2020 /PRNewswire/ -- Perseus Holdings USA, an immuno-oncology company focused on the development and commercialization of next-generation, immune-mediated technologies for the treatment of cancer, today announced the appointment of Dr. Mark Corrigan, an accomplished biotechnology executive, to the Company's Board of Directors. "Dr. Corrigan brings tremendous value to the Perseus Board of Directors as we advance our lead vaccine candidate into late stage clinical trials," said Buddy Long, chief executive officer of Perseus Holdings USA. "With his depth of business and scientific expertise leading large and small biopharmaceutical organizations and helping those companies achieve sustained growth, clinical excellence, and commercial success, Dr. Corrigan's insights and guidance will play a key role in shaping our clinical and commercialization strategies." Dr. Corrigan joins the Board of Perseus from Correvio Pharma Corp., where he served as chief executive officer from 2019-2020. Prior to Correvio, he was president of research and development at Tremeau Pharmaceuticals from 2016 to 2019. He currently serves on the Board of Tremeau Pharmaceuticals, where he was co-founder, and Wave Life Sciences. From 2010 to 2014, he served as president and chief executive officer of  Zalicus Inc., prior to their merger with Epirus Biopharmaceuticals in July 2014. Previously, Dr. Corrigan served as executive vice president of research and development for Sepracor Inc., a specialty pharmaceutical company (now Sunovion Pharmaceuticals, Inc.) from 2003 to 2009. Prior to joining Sepracor, Dr. Corrigan spent ten years with Pharmacia & Upjohn, where he served as group vice president of Global Clinical Research and Experimental Medicine. Before Dr. Corrigan entered the pharmaceutical industry, he spent five years in academic research at the University of North Carolina, School of Medicine and maintains a faculty appointment as adjunct professor in the department of Psychiatry. He is a Distinguished Fellow of the American Psychiatric Association. Dr. Corrigan has served on the board of directors of Cubist Pharmaceuticals, Avanir, Colucid Pharmaceuticals, Epirus (Chairman), Novelion (Executive Chairman), Nabriva Therapeutics and BlackThorn (Chairman). Dr. Corrigan holds a B.A. and a M.D. from the University of Virginia and received specialty training in psychiatry at Maine Medical Center and Cornell University. "I am pleased to join the Perseus Board at this exciting time in the Company's growth," said Dr. Corrigan. "The tumor lysate, particle-loaded, dendritic cell (TLPLDC ) technology promises a truly personalized medicine approach for patients to harness the power of their own immune systems to potentially cure their cancer. I look forward to collaborating with the Board management team as Perseus advances toward key clinical milestones, including leveraging the positive data from its Phase IIb trial of the TLPLDC vaccine which will set the stage for a registrational Phase 3 study for this lead program." About Perseus Holdings, LLC Perseus Holdings USA, LLC is an immuno-oncology company focused on the development and commercialization of next-generation, immune-mediated technologies for the treatment of cancer. Elios Therapeutics, LLC, a wholly owned subsidiary of Perseus Holdings, LLC., is a biopharmaceutical company developing a portfolio of innovative personalized therapeutic cancer vaccines targeting unmet medical needs across a broad range of tumor types. Perseus holds executive licenses for Elios' lead therapeutic candidate, the TLPLDC (tumor lysate, particle-loaded, dendritic cell) vaccine, a personalized therapeutic cancer vaccine that uses a proprietary particle delivery system to stimulate the body's immune system to recognize cancer cells as foreign pathogens and fight a patient's specific cancer. Perseus and its subsidiaries are investigating the clinical potential of TLPLDC in U.S. FDA clinical trials. For more information, please visit www.perseusholdingsusa.com . Forward-Looking Statements This document contains forward–looking statements relating to the Company's strategy, objectives, business development plans and financial position. All statements other than statements of historical facts included in this document, including, without limitation, statements regarding the Company's future financial position, strategy, anticipated investments, costs and results, status and results of clinical trials, size of patient population, plans, outcomes of product development efforts, and objectives of management for future operations, may be deemed to be forward–looking statements. You can identify forward-looking statements by words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative of those terms, and similar expressions that convey uncertainty or future events or outcomes. These forward–looking statements involve known and unknown risks, uncertainties, and other factors that may cause the Company's actual results, performance, or achievements or industry results to be materially different from those contemplated, projected, forecasted, estimated or budgeted, whether expressed or implied, by these forward–looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward–looking statements as a prediction of actual results. None of these forward–looking statements constitutes a guarantee of the future occurrence of such events or of actual results. These statements are based on data, assumptions, and estimates that the Company believes are reasonable. The forward–looking statements contained in this document are made only as of the date hereof. Except as otherwise required by law, the Company expressly disclaims any obligation or undertaking to release publicly any updates of any forward-looking statements contained in this document to reflect any change in its actual results, assumptions, expectations or any change in events, factors, conditions, or circumstances on which any forward–looking statement contained in this document is based. Contacts:

Perseus Investments

104 Investments

Perseus has made 104 investments. Their latest investment was in Cymbet as part of their Series E on April 4, 2013.

CBI Logo

Perseus Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/10/2013

Series E

Cymbet

$13.4M

No

1

3/27/2013

Convertible Note - II

Cymbet

$0.5M

No

1

12/5/2012

Debt - II

Connected Energy

$1.5M

No

1

11/28/2012

Private Equity

Subscribe to see more

$99M

Subscribe to see more

10

6/27/2012

Convertible Note

Subscribe to see more

$99M

Subscribe to see more

0

Date

4/10/2013

3/27/2013

12/5/2012

11/28/2012

6/27/2012

Round

Series E

Convertible Note - II

Debt - II

Private Equity

Convertible Note

Company

Cymbet

Cymbet

Connected Energy

Subscribe to see more

Subscribe to see more

Amount

$13.4M

$0.5M

$1.5M

$99M

$99M

New?

No

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

1

1

10

0

Perseus Portfolio Exits

32 Portfolio Exits

Perseus has 32 portfolio exits. Their latest portfolio exit was Aptus Health on September 30, 2019.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

9/30/2019

Acquired

$99M

7

5/8/2019

Acquired - II

$99M

1

7/13/2015

Acquired

$99M

1

11/11/2013

Acq - P2P

Subscribe to see more

$99M

Subscribe to see more

10

8/26/2013

Merger

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/30/2019

5/8/2019

7/13/2015

11/11/2013

8/26/2013

Exit

Acquired

Acquired - II

Acquired

Acq - P2P

Merger

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

7

1

1

10

10

Perseus Acquisitions

6 Acquisitions

Perseus acquired 6 companies. Their latest acquisition was Seismic Equipment Solutions on December 24, 2008.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

12/24/2008

$99M

Acquired

9/12/2008

Other Venture Capital

Subscribe to see more

$99M

$99M

Subscribe to see more

0

11/11/2005

Subscribe to see more

$99M

Subscribe to see more

0

4/14/2005

Subscribe to see more

$99M

Subscribe to see more

0

4/23/2004

Subscribe to see more

$99M

Subscribe to see more

0

Date

12/24/2008

9/12/2008

11/11/2005

4/14/2005

4/23/2004

Investment Stage

Other Venture Capital

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$99M

Note

Acquired

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

0

0

0

0

Perseus Partners & Customers

10 Partners and customers

Perseus has 10 strategic partners and customers. Perseus recently partnered with Greyrock Energy on May 5, 2016.

Date

Type

Business Partner

Country

News Snippet

Sources

5/31/2016

Partner

United States

Greyrock Energy : Perseus and Greyrock Announce Joint Venture to Monetize Flare Gas in Mexico

` Greyrock Energy , Inc. is excited to be partnering with Perseus to work on Flare Gas projects in Mexico and sees this as a significant opportunity to take flares out of service while producing premium fuels . '

3

2/24/2016

Vendor

United States

Perseus Picks Plexxi for Global Transport

Nashua , N.H. -- Plexxi a pioneer of converged networking and application-defined data center infrastructure , announced today that Perseus , the world 's leading provider of managed services for high-precision , high speed connectivity , has chosen Plexxi to deploy a next-generation network system to expand its service operations into 11 new major Asian markets and offer new services between 29 sites across the globe .

3

12/18/2015

Licensee

Perseus Enables RTM’s Global Expansion

NEW YORK & SAO PAULO -- -- Perseus and RTM announced the expansion of their existing relationship , bringing all RTM services onto the Perseus backbone , enabling service scalability across the globe .

1

11/11/2015

Partner

United States

Subscribe to see more

Subscribe to see more

10

6/26/2014

Partner

Netherlands

Subscribe to see more

Subscribe to see more

10

Date

5/31/2016

2/24/2016

12/18/2015

11/11/2015

6/26/2014

Type

Partner

Vendor

Licensee

Partner

Partner

Business Partner

Country

United States

United States

United States

Netherlands

News Snippet

Greyrock Energy : Perseus and Greyrock Announce Joint Venture to Monetize Flare Gas in Mexico

` Greyrock Energy , Inc. is excited to be partnering with Perseus to work on Flare Gas projects in Mexico and sees this as a significant opportunity to take flares out of service while producing premium fuels . '

Perseus Picks Plexxi for Global Transport

Nashua , N.H. -- Plexxi a pioneer of converged networking and application-defined data center infrastructure , announced today that Perseus , the world 's leading provider of managed services for high-precision , high speed connectivity , has chosen Plexxi to deploy a next-generation network system to expand its service operations into 11 new major Asian markets and offer new services between 29 sites across the globe .

Perseus Enables RTM’s Global Expansion

NEW YORK & SAO PAULO -- -- Perseus and RTM announced the expansion of their existing relationship , bringing all RTM services onto the Perseus backbone , enabling service scalability across the globe .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

3

3

1

10

10

Perseus Team

13 Team Members

Perseus has 13 team members, including current Chief Executive Officer, Frank H. Pearl.

Name

Work History

Title

Status

Frank H. Pearl

Chief Executive Officer

Current

Susan R. Inouye

Chief Financial Officer

Current

Frank Pignal

Chief Technology Officer

Current

Dave M. Davis

Senior Managing Director

Current

John C. Fox

Senior Managing Director

Current

Name

Frank H. Pearl

Susan R. Inouye

Frank Pignal

Dave M. Davis

John C. Fox

Work History

Title

Chief Executive Officer

Chief Financial Officer

Chief Technology Officer

Senior Managing Director

Senior Managing Director

Status

Current

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.